Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications.
about
Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK CellsT-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effectAdoptive cell therapy for sarcomaAntiviral T-cell therapyManufacturing Natural Killer Cells as Medicinal ProductsEngineered T cells for cancer treatmentClearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.NK cell-based immunotherapy for malignant diseases.Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy.Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspectiveDevelopment of NK cell expansion methods using feeder cells from human myelogenous leukemia cell line.Enhanced cytotoxicity of natural killer cells following the acquisition of chimeric antigen receptors through trogocytosisHuman cell-based artificial antigen-presenting cells for cancer immunotherapy.GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo.Low-dose ionizing radiation induces direct activation of natural killer cells and provides a novel approach for adoptive cellular immunotherapyAntigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity.Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity.Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patientsOptimizing the production of suspension cells using the G-Rex "M" series.Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies.Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cellsThe TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemiaClinical grade purification and expansion of NK cell products for an optimized manufacturing protocolGrowth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.Bone marrow produces sufficient alloreactive natural killer (NK) cells in vivo to cure mice from subcutaneously and intravascularly injected 4T1 breast cancer.CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myelomaNovel Strategy to Expand Super-Charged NK Cells with Significant Potential to Lyse and Differentiate Cancer Stem Cells: Differences in NK Expansion and Function between Healthy and Cancer Patients.Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation.Clinical grade purification and expansion of natural killer cells.Umbilical cord blood graft engineering: challenges and opportunities.Natural killer cells as a promising tool to tackle cancer-A review of sources, methodologies, and potentials.CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies.Advances in clinical NK cell studies: Donor selection, manufacturing and quality controlImmunosenescence: limitations of natural killer cell-based cancer immunotherapy.Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation.Developmental and Functional Control of Natural Killer Cells by Cytokines.Characterization and ex vivo Expansion of Human Placenta-Derived Natural Killer Cells for Cancer Immunotherapy.Large-Scale Culture and Genetic Modification of Human Natural Killer Cells for Cellular Therapy.Natural killer cell therapy for cancer: delivering on a promise.Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients.
P2860
Q26751020-BE3CDEBF-ED23-4EA2-A692-E5ADBD744062Q26826830-F82AB25A-6BE9-4C07-837C-FE449AB305BDQ27009541-543D435C-2D6C-4B21-857C-E379AC851FAEQ27028006-B17A794B-3C45-44E6-895C-BFEAB5043D5BQ28069992-01E690EB-63B6-4891-9BBF-DD19FFC45600Q33578792-A234F3AE-0CE2-42C8-AD5C-457193858CC9Q33781150-CF1188F3-CCFA-40E0-9E5D-F7C3DF842196Q33827433-CFEF5C87-4544-4FDE-8384-E8C879BCA456Q33905311-287B1540-5D8E-4D91-AC3E-597913954815Q34180695-2AFFBEF3-C23A-4034-BEF3-781E2A3AE383Q34302464-D968B51D-D382-490B-978A-844CDC08B008Q34338159-8E6DD897-4EBC-4834-B4F6-56DB12881E6FQ34391263-E2C22169-41C8-4086-A07A-6030568A9679Q34551581-406C23BA-8B17-4F29-B921-868757908436Q34712771-AD09B0CD-E49D-4B5A-8129-3018596F3B8BQ35034803-DAE207B9-3318-431A-9614-A726F461EB5CQ35142912-4B71049B-AF1E-409D-A325-0C31BDE071F3Q35157421-B886B7C3-DE5C-4B3D-8F25-E1B95483C0D3Q35184232-9C6DA930-DBDE-43EE-B997-8B3C328FEB32Q35600095-48C28A78-D4A9-436A-AFF3-AE1F3CA7462EQ36470354-12D4A513-7EA2-41FE-A933-65822FEE4FCFQ36772346-F8758098-E3C1-4138-8055-88A7B10D99E3Q36850695-49409A98-5DF8-48AE-8C12-810C1F75BA06Q36856792-995530F5-BC18-48D1-A895-9B7FF9575B7CQ37590606-303E1821-1C6B-419B-815B-98CD29849C3EQ37666309-50E6111C-54FE-4C2B-B399-B0C905F51426Q37737545-358E6B54-2F0A-4F96-90F6-8A645A9DD06BQ38105123-EDB52661-6423-48E2-B49C-DB14C5BBA9C4Q38221228-8C7ADC81-53F9-4DCA-9B54-74C86B5EE31AQ38514503-40DE5DD8-D3B4-43F3-88F1-6D0E88CC81C5Q38687810-89052152-7800-4E9E-B2D0-94FA837FC4C9Q38783833-FBE92038-4D57-4472-8558-F410A9995104Q38824360-FB4F34EC-62ED-445B-A538-D8121C6D3CB7Q38928938-CB929034-D7E0-4C32-9399-193098702927Q39296861-B7877C26-EA4D-41E9-BA83-7FA3C7D3335EQ40086298-5E69AACD-658C-45EC-9A2B-7C9854F0BE0FQ40248410-5A55F424-3DE7-4D38-AB0E-21D7136473B2Q40755381-DA56331E-91A5-42AB-A93E-96EF192A0786Q44360875-D4E766FD-49DD-45E1-952B-24BEF9DBA59FQ44823723-858675A5-5223-4D51-B493-30D20ACDA723
P2860
Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Large-scale ex vivo expansion ...... lls for clinical applications.
@ast
Large-scale ex vivo expansion ...... lls for clinical applications.
@en
type
label
Large-scale ex vivo expansion ...... lls for clinical applications.
@ast
Large-scale ex vivo expansion ...... lls for clinical applications.
@en
prefLabel
Large-scale ex vivo expansion ...... lls for clinical applications.
@ast
Large-scale ex vivo expansion ...... lls for clinical applications.
@en
P2093
P2860
P1433
P1476
Large-scale ex vivo expansion ...... lls for clinical applications.
@en
P2093
Adrian P Gee
Amberly Moreno-Bost
April G Durett
Cliona M Rooney
Dario Campana
Elaine Coustan-Smith
Frits Vanrhee
P2860
P304
P356
10.3109/14653249.2012.700767
P577
2012-08-17T00:00:00Z